Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05867485
Other study ID # AralikKilisU1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2022
Est. completion date July 1, 2022

Study information

Verified date May 2023
Source Kilis 7 Aralik University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aimed to evaluate the impact of specialized discharge education on the daily life activities and quality of life of geriatric patients hospitalized in COVID-19 wards. The motivation behind this study stems from the vulnerability of elderly patients during the COVID-19 pandemic and the necessity of tailored education to support their daily life activities and enhance their quality of life after discharge. The primary objective of this article is to determine the specific type of specialized discharge education that geriatric patients in COVID-19 wards require to improve their ability to sustain daily life activities and enhance their quality of life. The central idea of this study is that providing specialized discharge education to geriatric patients in COVID-19 wards can result in improvements in their daily life activities and quality of life. The main findings of the study demonstrate a significant enhancement in daily life activities and quality of life among patients who received specialized discharge education. These individuals exhibited increased independence in mobility, improved performance in daily life activities, and reported an overall improvement in their quality of life. These findings underscore the significance of specialized discharge education for geriatric patients hospitalized in COVID-19 wards and highlight its positive impact on their health outcomes and quality of life.


Description:

Purpose: This research aimed to determine the impact of specialized discharge training on the daily living activities and quality of life of geriatric patients admitted to the COVID-19 ward. Materials and Methods: A quasi-experimental study was conducted on geriatric patients admitted to a training and research hospital's COVID-19 ward between April 1 and July 1, 2022. A control group of 40 individuals and a study group of 40 individuals, both meeting the inclusion criteria, were established. Research data were collected using the Descriptive Features Form, Katz Index of Independence in Activities of Daily Living, and SF-12 Quality of Life Scale.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date July 1, 2022
Est. primary completion date June 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years to 99 Years
Eligibility Inclusion Criteria: - The inclusion criteria for the study were as follows; Willingness to participate in the research, Age 65 and over, Hospitalized geriatric patients in the pandemic service, Openness to communication and cooperation, Sound mental health, Absence of sensory impairments such as vision, hearing, and speech. Exclusion Criteria: - patients who do not meet the inclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Other:
COVID-19 Discharge Education
A discharge education brochure has been developed based on information from the literature to complement the verbal information provided to patients. The content of the education brochure includes the following: Information about the spread of the virus and precautions to be taken. Guidelines for cleanliness and disinfection of the environment. Precautions regarding personal and wearable items. Information about food and beverages. Guidelines for personal hygiene practices. Information about quarantine and isolation. Guidelines for maintaining health and care (e.g., respiratory hygiene, cough etiquette, movement, range of motion exercises) (CDC, 2019; Ministry of Health of Turkey, 2020; CDC 2019 A-B-C-D).

Locations

Country Name City State
Turkey Islam Kilis

Sponsors (1)

Lead Sponsor Collaborator
Kilis 7 Aralik University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Katz Daily Life Activities Scale (GYA): The Katz Daily Life Activities Scale (GYA) was developed by Katz and colleagues in 1963 to assess activities essential for daily life. The scale measures the scores of key elements related to daily life activities, such as bathing, dressing, toileting, mobility, continence, and feeding. The GYA index categorizes scores as dependent (0-6 points), partially dependent (7-12 points), and independent (13-18 points). The scale has been translated into Turkish and validated by Yardimci E., with a Cronbach's alpha coefficient of 0.73. Response options in the Katz GYA scale include "independent," "partially dependent," and "dependent." 0 day
Primary Quality of Life Scale (SF-12): The SF-12 Quality of Life Scale is a widely used instrument that assesses the quality of life over the past four weeks, encompassing various age and disease groups. The Turkish version of the scale, including its reliability and validity study, was conducted by Soylu and Kütük (2022). The SF-12 consists of 12 questions selected from the SF-36 Quality of Life Scale. It comprises eight sub-dimensions and 12 items, including physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health. The SF-12 yields two summary scores: the Physical Component Summary Score (PCSS) and the Mental Component Summary Score (MCSS). The scale demonstrates a Cronbach's alpha coefficient of 0.72. 0 day
Primary Katz Daily Life Activities Scale (GYA): The Katz Daily Life Activities Scale (GYA) was developed by Katz and colleagues in 1963 to assess activities essential for daily life. The scale measures the scores of key elements related to daily life activities, such as bathing, dressing, toileting, mobility, continence, and feeding. The GYA index categorizes scores as dependent (0-6 points), partially dependent (7-12 points), and independent (13-18 points). The scale has been translated into Turkish and validated by Yardimci E., with a Cronbach's alpha coefficient of 0.73. Response options in the Katz GYA scale include "independent," "partially dependent," and "dependent." 1 month
Primary Quality of Life Scale (SF-12): The SF-12 Quality of Life Scale is a widely used instrument that assesses the quality of life over the past four weeks, encompassing various age and disease groups. The Turkish version of the scale, including its reliability and validity study, was conducted by Soylu and Kütük (2022). The SF-12 consists of 12 questions selected from the SF-36 Quality of Life Scale. It comprises eight sub-dimensions and 12 items, including physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health. The SF-12 yields two summary scores: the Physical Component Summary Score (PCSS) and the Mental Component Summary Score (MCSS). The scale demonstrates a Cronbach's alpha coefficient of 0.72. 1 month
See also
  Status Clinical Trial Phase
Suspended NCT04901676 - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04534478 - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Phase 4
Active, not recruiting NCT05002517 - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Phase 3
Completed NCT05008393 - Efficacy of PJS-539 for Adult Patients With COVID-19. Phase 2
Completed NCT04569877 - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia Phase 2
Not yet recruiting NCT05286255 - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias Phase 1
Completed NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Recruiting NCT06113432 - CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study N/A
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT04615429 - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19 Phase 2
Completed NCT05047653 - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting NCT05047016 - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY N/A
Active, not recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 2
Recruiting NCT06113757 - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease N/A
Completed NCT05504655 - N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
Active, not recruiting NCT05035524 - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19 N/A
Completed NCT05065879 - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes Phase 4
Withdrawn NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Withdrawn NCT04460105 - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia Phase 1
Suspended NCT04901689 - Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation Phase 3